Related Experiment Video

Updated: Mar 21, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

[Resistance to anti-angiogenic therapy: a clinical and scientific current issue]

Yuchen Gu1, He Lu1, Catherine Boisson-Vidal2

  • 1Inserm UMR-S1165, université Paris Diderot, Sorbonne Paris Cité, 1, avenue Claude Vellefaux, 75010 Paris, France.

Medecine Sciences : M/S
|May 4, 2016
PubMed

Insights

Anti-angiogenic agents show promise in blocking tumor growth and improving drug delivery, despite limitations in clinical trials. Research is ongoing to address resistance and toxicity, and identify biomarkers for effective cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Anti-angiogenic agents are a promising strategy for cancer therapy.
  • Their clinical application is limited by resistance and toxicity.
  • However, they have demonstrated efficacy in extending survival for various cancers.

Purpose of the Study:

  • To review the current status of anti-angiogenic agents in cancer treatment.
  • To highlight the challenges and potential of this therapeutic approach.
  • To emphasize the importance of biomarker identification.

Main Methods:

  • Literature review of anti-angiogenic agents in cancer therapy.
  • Analysis of clinical trial data and outcomes.
  • Discussion of resistance mechanisms and toxicity profiles.

Main Results:

  • Anti-angiogenic therapy has shown survival benefits in colon, breast, kidney, lung, and liver cancers.
  • Resistance and toxicity remain significant challenges.
  • Biomarker identification is crucial for optimizing treatment response.

Conclusions:

  • Anti-angiogenic agents remain a valuable therapeutic tool in oncology.
  • Further research is needed to overcome resistance and toxicity.
  • Identifying predictive biomarkers is essential for personalized anti-angiogenic therapy.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K
Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.5K